Do analysts prefer CAPS or CLWT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Euro Tech 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, CAPS or CLWT?

Euro Tech has lower revenue, but higher earnings than Capstone Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Capstone Therapeutics $48.11M 0.05 -$21.23M -$3.35 N/A Euro Tech $13.27M 0.88 $160K N/A N/A

Does the media refer more to CAPS or CLWT?

In the previous week, Euro Tech had 6 more articles in the media than Capstone Therapeutics. MarketBeat recorded 8 mentions for Euro Tech and 2 mentions for Capstone Therapeutics. Euro Tech's average media sentiment score of 0.93 beat Capstone Therapeutics' score of 0.91 indicating that Euro Tech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capstone Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Euro Tech 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend JBDI or CAPS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JBDI 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, JBDI or CAPS?

JBDI has higher earnings, but lower revenue than Capstone Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio JBDI $8.52M 3.83 $120K N/A N/A Capstone Therapeutics $48.11M 0.05 -$21.23M -$3.35 N/A

Does the media refer more to JBDI or CAPS?

In the previous week, JBDI had 9 more articles in the media than Capstone Therapeutics. MarketBeat recorded 11 mentions for JBDI and 2 mentions for Capstone Therapeutics. Capstone Therapeutics' average media sentiment score of 0.91 beat JBDI's score of 0.30 indicating that Capstone Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment JBDI 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Capstone Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CAPS or MWG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Multi Ways 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, CAPS or MWG?

Multi Ways has lower revenue, but higher earnings than Capstone Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Capstone Therapeutics $48.11M 0.05 -$21.23M -$3.35 N/A Multi Ways $44.77M 0.17 $1.79M N/A N/A

Do analysts rate CAPS or INEO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 INNEOVA 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, CAPS or INEO?

INNEOVA has higher revenue and earnings than Capstone Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Capstone Therapeutics $48.11M 0.05 -$21.23M -$3.35 N/A INNEOVA $58.42M 0.12 -$400K N/A N/A

Do analysts rate CAPS or SOS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SOS 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, CAPS or SOS?

Capstone Therapeutics has higher earnings, but lower revenue than SOS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Capstone Therapeutics $48.11M 0.05 -$21.23M -$3.35 N/A SOS $154.29M 0.02 -$97.32M N/A N/A

Does the media prefer CAPS or SOS?

In the previous week, SOS had 1 more articles in the media than Capstone Therapeutics. MarketBeat recorded 3 mentions for SOS and 2 mentions for Capstone Therapeutics. Capstone Therapeutics' average media sentiment score of 0.91 beat SOS's score of 0.46 indicating that Capstone Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capstone Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SOS 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Capstone Therapeutics (CAPS) Competitors

$0.12 -0.01 (-6.83%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$0.12 0.00 (-1.77%)

As of 08:44 AM Eastern

Compare

CAPS vs. CLWT, JBDI, MWG, INEO, and SOS

Should you buy Capstone Therapeutics stock or one of its competitors? Capstone Therapeutics's main competitors and comparable companies include Euro Tech (CLWT), JBDI (JBDI), Multi Ways (MWG), INNEOVA (INEO), and SOS (SOS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "trading companies & distributors" industry.

How does Capstone Therapeutics compare to Euro Tech?

Capstone Therapeutics (NASDAQ:CAPS) and Euro Tech (NASDAQ:CLWT) are both small-cap industrials companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

2.6% of Capstone Therapeutics shares are held by institutional investors. Comparatively, 2.9% of Euro Tech shares are held by institutional investors. 39.3% of Capstone Therapeutics shares are held by company insiders. Comparatively, 79.0% of Euro Tech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Euro Tech had 6 more articles in the media than Capstone Therapeutics. MarketBeat recorded 8 mentions for Euro Tech and 2 mentions for Capstone Therapeutics. Euro Tech's average media sentiment score of 0.93 beat Capstone Therapeutics' score of 0.91 indicating that Euro Tech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capstone Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Euro Tech	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Euro Tech	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Euro Tech has lower revenue, but higher earnings than Capstone Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$48.11M	0.05	-$21.23M	-$3.35	N/A
Euro Tech	$13.27M	0.88	$160K	N/A	N/A

Capstone Therapeutics has a beta of -1.5, indicating that its share price is 250% less volatile than the broader market. Comparatively, Euro Tech has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

Euro Tech has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. Euro Tech's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-36.51%	-144.43%	-40.48%
Euro Tech	N/A	N/A	N/A

Summary

Euro Tech beats Capstone Therapeutics on 11 of the 12 factors compared between the two stocks.

How does Capstone Therapeutics compare to JBDI?

JBDI (NASDAQ:JBDI) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap industrials companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

JBDI has a beta of -1.04, suggesting that its stock price is 204% less volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.5, suggesting that its stock price is 250% less volatile than the broader market.

2.6% of Capstone Therapeutics shares are held by institutional investors. 39.3% of Capstone Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

JBDI has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. JBDI's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JBDI	N/A	N/A	N/A
Capstone Therapeutics	-36.51%	-144.43%	-40.48%

JBDI has higher earnings, but lower revenue than Capstone Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JBDI	$8.52M	3.83	$120K	N/A	N/A
Capstone Therapeutics	$48.11M	0.05	-$21.23M	-$3.35	N/A

In the previous week, JBDI had 9 more articles in the media than Capstone Therapeutics. MarketBeat recorded 11 mentions for JBDI and 2 mentions for Capstone Therapeutics. Capstone Therapeutics' average media sentiment score of 0.91 beat JBDI's score of 0.30 indicating that Capstone Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
JBDI	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Capstone Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JBDI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

JBDI beats Capstone Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Capstone Therapeutics compare to Multi Ways?

Capstone Therapeutics (NASDAQ:CAPS) and Multi Ways (NYSE:MWG) are both small-cap industrials companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, Capstone Therapeutics had 2 more articles in the media than Multi Ways. MarketBeat recorded 2 mentions for Capstone Therapeutics and 0 mentions for Multi Ways. Capstone Therapeutics' average media sentiment score of 0.91 beat Multi Ways' score of 0.00 indicating that Capstone Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Capstone Therapeutics	Positive
Multi Ways	Neutral

Capstone Therapeutics has a beta of -1.5, meaning that its share price is 250% less volatile than the broader market. Comparatively, Multi Ways has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Multi Ways has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. Multi Ways' return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-36.51%	-144.43%	-40.48%
Multi Ways	N/A	N/A	N/A

Multi Ways has lower revenue, but higher earnings than Capstone Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$48.11M	0.05	-$21.23M	-$3.35	N/A
Multi Ways	$44.77M	0.17	$1.79M	N/A	N/A

2.6% of Capstone Therapeutics shares are owned by institutional investors. Comparatively, 0.8% of Multi Ways shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Multi Ways	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Capstone Therapeutics and Multi Ways tied by winning 6 of the 12 factors compared between the two stocks.

How does Capstone Therapeutics compare to INNEOVA?

Capstone Therapeutics (NASDAQ:CAPS) and INNEOVA (NASDAQ:INEO) are both small-cap industrials companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

INNEOVA has higher revenue and earnings than Capstone Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$48.11M	0.05	-$21.23M	-$3.35	N/A
INNEOVA	$58.42M	0.12	-$400K	N/A	N/A

In the previous week, Capstone Therapeutics had 1 more articles in the media than INNEOVA. MarketBeat recorded 2 mentions for Capstone Therapeutics and 1 mentions for INNEOVA. INNEOVA's average media sentiment score of 1.82 beat Capstone Therapeutics' score of 0.91 indicating that INNEOVA is being referred to more favorably in the news media.

Company	Overall Sentiment
Capstone Therapeutics	Positive
INNEOVA	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
INNEOVA	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

2.6% of Capstone Therapeutics shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

INNEOVA has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. INNEOVA's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-36.51%	-144.43%	-40.48%
INNEOVA	N/A	N/A	N/A

Capstone Therapeutics has a beta of -1.5, indicating that its stock price is 250% less volatile than the broader market. Comparatively, INNEOVA has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

Summary

INNEOVA beats Capstone Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Capstone Therapeutics compare to SOS?

Capstone Therapeutics (NASDAQ:CAPS) and SOS (NYSE:SOS) are both small-cap industrials companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

SOS has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. SOS's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-36.51%	-144.43%	-40.48%
SOS	N/A	N/A	N/A

2.6% of Capstone Therapeutics shares are owned by institutional investors. Comparatively, 1.9% of SOS shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by company insiders. Comparatively, 2.7% of SOS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Capstone Therapeutics has higher earnings, but lower revenue than SOS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$48.11M	0.05	-$21.23M	-$3.35	N/A
SOS	$154.29M	0.02	-$97.32M	N/A	N/A

In the previous week, SOS had 1 more articles in the media than Capstone Therapeutics. MarketBeat recorded 3 mentions for SOS and 2 mentions for Capstone Therapeutics. Capstone Therapeutics' average media sentiment score of 0.91 beat SOS's score of 0.46 indicating that Capstone Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capstone Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SOS	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SOS	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Capstone Therapeutics has a beta of -1.5, indicating that its share price is 250% less volatile than the broader market. Comparatively, SOS has a beta of 2.67, indicating that its share price is 167% more volatile than the broader market.

Summary

SOS beats Capstone Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Capstone Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAPS vs. The Competition

Export

Metric	Capstone Therapeutics	Trading Companies & Distributors Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$2.74M	$9.42B	$10.18B	$13.21B
Dividend Yield	N/A	3.41%	96.64%	22.89%
P/E Ratio	N/A	44.36	23.43	19.81
Price / Sales	0.05	23.06	275.39	81.34
Price / Cash	N/A	50.18	23.80	53.04
Price / Book	0.09	3.87	4.74	6.03
Net Income	-$21.23M	$377.83M	$614.12M	$380.34M
7 Day Performance	-11.35%	2.26%	-0.99%	-2.34%
1 Month Performance	-27.07%	3.43%	-2.68%	-5.31%
1 Year Performance	-90.80%	10.81%	1.28%	-2.94%

Capstone Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAPS Capstone Therapeutics	0.3788 of 5 stars	$0.12 -6.8%	N/A	-88.9%	$2.74M	$48.11M	N/A	93
CLWT Euro Tech	1.4233 of 5 stars	$2.15 +58.1%	N/A	+24.6%	$10.13M	$13.27M	N/A	24	News Coverage Short Interest Decrease Gap Down High Trading Volume
JBDI JBDI	0.8072 of 5 stars	$0.98 -2.0%	N/A	-11.1%	$9.51M	$8.52M	N/A	99	Trending News Gap Down
MWG Multi Ways	N/A	$1.55 +5.7%	N/A	-46.4%	$7.98M	$44.77M	N/A	92
INEO INNEOVA	0.9014 of 5 stars	$0.56 +3.5%	N/A	-38.9%	$6.63M	$58.42M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAPS) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Capstone Therapeutics (CAPS) Competitors

CAPS vs. CLWT, JBDI, MWG, INEO, and SOS

How does Capstone Therapeutics compare to Euro Tech?

Summary

How does Capstone Therapeutics compare to JBDI?

Summary

How does Capstone Therapeutics compare to Multi Ways?

Summary

How does Capstone Therapeutics compare to INNEOVA?

Summary

How does Capstone Therapeutics compare to SOS?

Summary

Media Sentiment Over Time

CAPS vs. The Competition

Capstone Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Capstone Therapeutics (CAPS) Competitors

CAPS vs. CLWT, JBDI, MWG, INEO, and SOS

How does Capstone Therapeutics compare to Euro Tech?

Do insiders & institutionals have more ownership in CAPS or CLWT?

Does the media refer more to CAPS or CLWT?

Do analysts prefer CAPS or CLWT?

Which has stronger valuation and earnings, CAPS or CLWT?

Which has more risk & volatility, CAPS or CLWT?

Is CAPS or CLWT more profitable?

Summary

How does Capstone Therapeutics compare to JBDI?

Which has more volatility and risk, JBDI or CAPS?

Do institutionals and insiders have more ownership in JBDI or CAPS?

Is JBDI or CAPS more profitable?

Which has stronger earnings and valuation, JBDI or CAPS?

Does the media refer more to JBDI or CAPS?

Do analysts recommend JBDI or CAPS?

Summary

How does Capstone Therapeutics compare to Multi Ways?

Does the media prefer CAPS or MWG?

Which has more risk & volatility, CAPS or MWG?

Is CAPS or MWG more profitable?

Which has preferable earnings & valuation, CAPS or MWG?

Do institutionals & insiders have more ownership in CAPS or MWG?

Do analysts recommend CAPS or MWG?

Summary

How does Capstone Therapeutics compare to INNEOVA?

Which has stronger earnings and valuation, CAPS or INEO?

Does the media prefer CAPS or INEO?

Do analysts rate CAPS or INEO?

Do insiders & institutionals have more ownership in CAPS or INEO?

Is CAPS or INEO more profitable?

Which has more risk & volatility, CAPS or INEO?

Summary

How does Capstone Therapeutics compare to SOS?

Is CAPS or SOS more profitable?

Do insiders and institutionals have more ownership in CAPS or SOS?

Which has better valuation and earnings, CAPS or SOS?

Does the media prefer CAPS or SOS?

Do analysts rate CAPS or SOS?

Which has more volatility & risk, CAPS or SOS?

Summary

Media Sentiment Over Time

CAPS vs. The Competition

Capstone Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools